FDA cleared Wello offers an FDA Class II non-contact medical device powered by WelloAI that detects potential infections before symptoms, presenting a proactive health management solution ideal for large workplaces and institutions seeking infection reduction and absenteeism reduction.

Healthcare partnerships Strategic collaborations with Canon Solutions America and Lotus Biosecurity indicate a channel-friendly approach; explore co-selling with office healthcare providers, security firms, and corporate wellness programs to scale deployments.

Workplace focus Target organizations with high footfall and critical operations (corporate campuses, manufacturing sites, healthcare facilities) where automated no-touch temperature screening can reduce infection risk and protect business continuity.

Growth potential Revenue range alongside a small-to-mid sized team suggests a lean sales footprint with room for partner-enabled selling, strategic alliances, and scalable contract-driven deals across mid-market to enterprise-sized customers.

Market traction Recent acquisitions and partnerships ( Maple acquisition, LotusBiosecurity partnership ) signal momentum; leverage case studies and reference deployments to build credibility with global enterprises seeking AI-driven health resilience.